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HYPERURICEMIA AND ARTERIAL HYPERTENSION IN
GENERAL PRACTICII
Recently, the issue of correlation between elevated level of uric acid
(UA), arterial hypertension (AH) and other metabolic disorders is of great
interest fbr researchers. lt has been proved by evidence that hyperuricemia (HU)
is an independent factor for coronary heart disease cardior.ascular morbidity and
related morrality in patients with coronary heart disease [8,1548; 3,287f, chronic
and acute heart failure [2,78], AH and prehypertension and rnetabolic syndrome
[9,6]. How'ever, UA is more significant &s a risk factor for cardiovascular events
in patients with AFI, proved by the data of perspective srudies [5,160]. It has
been proved by evidence thar elevation of UA lelel in blood plasma fiay
precede the occurrence of AH in apparently healthy individuals [|0, 10801. In
this way, essential hyperlension has been observed in25o/a of patients with All
before treatment and 50Yo ot' patients, treated with diuretics. Furthermore,
arterial hypertension is more often revealed in individuals with hyperuricemia
than with normal UA level in blood plasma. Positive dynamics between the
level of diastoiic Al{ and UA and enlargement of left ventricular hypertrophy in
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patients with AH with hyperuricemia as compared with patients with
normoruricemia [5, I 60].
The role of UA as an independent predictor of cardiovascular events and
related monality in patients with AH has been investigated by SHEP study,
involved 4327 patients. aged above 60 years with isolated systolic hypertension
who were treated for 5 years with thiazide diuretics, supplemented with
atenololum or reserpinum, if necessary [6,] 154] .
The findinp ofthe present study validated the linear dependence ofthe
number of cardiovascular events from the initial UA level, with the exception of
strokes. It has been proved by evidence that diuretic therapy in therapeutic doses
led to elevation of UA level in halfof the patients during the year.
The reasons for hyperuricemia are variable. Elevation of UA level may be
caused by kidney damage, frequent consumption of fafty meats, seafocd,
alcohol, as well as obesity that increase the risk for hyperuricemia by 3 times.
Numerous medications, including loop and thiazide diuretics can change and
impair the renal UA clearance.
Hyperwicemia is also recognized as an important component of the
metabolic syndrome (MS). ln initial diagnostics of MS hyperuricemia is
considered as tlre main component with hypertension and hyperlipidemia.
PIUMA Study investigated the important role of UA as an independent
predictor of cardiovascular morbidity and mortality, involved 1720 patients with
AH who have been obsen'ed for 12 years. In patients with AH with initial UA
level grater than 0,396 mmol/l the risk of cardioyascular events, fatal
cardiovascular events and total mortality were significantly higher than in
patients with UA level from 0,268 mmol/l to 0,309 mmoVl [ 10,1076].
Consequently, the following evidences of UA correlation with AH
development exist to date:
- elevated UA level predicts the developrnent of hypertension;
'elevated uric acid ler.el is observed in25-600/o ofpatients with untreated
hypertension and almost 90% of adolescents with essential hype,rtension and the
recent debut;
- lowering of UA level with xanthine oxidase inhibiton reduces blood
pressure in adolescents with arterial hypertension.
Clarifying the relationship of UA to the risk of cardiovascular disease is
of clinical sigrrificance. Firstly, the incidence rate and spread of gout and HU
has been registered in the society. Secondly, asymptomatic HU is not an
indication lbr urine-lowering therapy
Accordingly, the need to develop rnethods for correcting asymptomatic
hyperuricemia is crucial. The reasonability of administration of xanthine oxidase
inhibitors (Allopurinolum) to patients with cardiovascular disease requires
ralidation in randomized trials. Therefore, it is crucial to perform selection of
drugs appropriately for patients with AH and hyperuricemia for positive impact
on purine metabolism and other conditions, related to its disorder.
A successful AH confrol is one of the components of the effective HU
keatment in toto that should meet the general requirements for antihypertensive
therapy 11,20]. Antihypertensive agents are to be of a positive impact on the
purini and lipid merabolism, insulin sensitivity with no negative impact on
manifested nephropathy. lnterrelation of complicated metabolic process should
be taken into ionsideration in paticnts with All and FIU not to inclease the risk
of therapeutical I y-ind uced gout.
Similarly, drug metabolic safety is of great importance, as well as drug
selection, possessing the ability to reduce the risk of cardiovascular
complications. lt has been shown that there is no safe type of diuretics' atl drugs
of tliis group inhibir UA excretion, Ieading to HU; p-blockers also are not the
drugs olchoice in AH and HU conjunction, as they increase insulin- resistance,
hyperinsulinemia, increasinC HU'
Prescntly, it is known that calcium antagonists of dihydropyridine series
of prolonged effect lAmlodipinunr) are metabolically neutral agents' prcmoting
optimal AH control; ACE inhibitors, angiotensin ll receptots blockers with
pc,sitive hyperuricemial effect due to reduced urate reabsorptian in the proximal
ildn"y tubut *. Moteover, Losartanum is able to eliminate HU, associated with
adminishation of thiazide and thiazide-like diuretics'
None of the sartana, with the exception of Losarlanunl are able to reduce
UA in combination with diuretics U,3041.
Conclusiou:
1. consequently, the reliable correlation betryeen hyperuricemia ancl AH
has been established to date.
2. Such metabolically neutral agents as dihydropyridine caicium
antagonists of dihydropyridine series, ACE inhibitom, angiotensin II receptors
blockers should be used tbr effbctive AH control.
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